Yael is a Partner at aMoon Velocity & Head of aMoon Alpha, an internal value creation unit charged with translating aMoon’s unique scale, talent, and global network into concrete competitive advantages and growth opportunities for our portfolio companies. At Velocity, Yael manages sourcing, evaluation, and strategic collaborations, as well as providing support to aMoon in a cross-functional manner to strengthen pharma partnerships and collaborations.
With 15 years of experience in the Healthcare space, Yael's professional journey as a HealthTech investor is underlined by a patient-centric drive for success. Committed to advancing Israel’s HealthTech growth engine, she believes that through strategic investments we are able to transform and improve the lives of patients.
As General Manager of Medison Ventures, she has led multiple licensing deals, scouting initiatives for over 15 pharmaceutical companies and has been collaborating with academia and the biotech industry – and led series A investments (and onwards) focused primarily on orphan drugs and genetic diseases.
Previously, Yael led Medical Affairs for the Rare Disease Division of Medison Pharma launching over 10 products. Yael advised to multiple platform companies on platform to product strategy and early partnership deal structures.
With her managerial experience, Yael has led collaborations and effective teamwork across functions and companies. Yael co-founded Andlit Therapeutics and WE@HealthTech – a collaboration with 8400 to build-up female leadership talent in HealthTech.
Yael holds academic degrees in molecular genetics (PhD, Post doc) and a DMD from the Hebrew University of Jerusalem and the Weizmann Institute of Sciences. She is a co-author of multiple scientific publications and is highly involved in pro-bono medical-scientific support of the rare disease community.
